Acticor Biotech SAS
EPA:ALACT.PA
0.362 (EUR) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 0 | 0 | 0 | 0.05 | 8.828 | 13.84 | 17.028 | 19.766 | 17.536 | 15.017 | 10.568 | 6.703 |
Cost of Revenue
| 0.728 | 0.086 | 0.1 | 0.099 | 0.075 | 0 | 7.062 | 9.297 | 12.623 | 11.588 | 9.688 | 7.636 | 5.363 | 4.166 |
Gross Profit
| -0.728 | -0.086 | -0.1 | -0.099 | -0.075 | 0.05 | 1.766 | 4.543 | 4.404 | 8.178 | 7.848 | 7.381 | 5.205 | 2.537 |
Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 1 | 0.2 | 0.328 | 0.259 | 0.414 | 0.448 | 0.492 | 0.493 | 0.379 |
Reseach & Development Expenses
| 14.49 | 10.761 | 9.136 | 5.851 | 3.616 | 4.092 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 0 | 3.569 | 2.312 | 0.762 | 0.826 | 1.553 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Selling & Marketing Expenses
| 0 | 0 | 0.476 | 0.043 | 0.064 | 0.059 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 4.88 | 3.569 | 2.788 | 0.805 | 0.89 | 1.612 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Expenses
| -0.065 | 0.772 | -0.093 | 0.92 | 0.658 | 0.177 | 9.551 | 4.642 | 5.97 | 5.963 | 5.185 | 4.306 | 2.727 | 1.819 |
Operating Expenses
| 19.435 | 15.102 | 11.831 | 7.576 | 5.164 | 5.881 | 9.551 | 4.642 | 5.97 | 5.963 | 5.185 | 4.306 | 2.727 | 1.819 |
Operating Income
| -20.163 | -15.121 | -11.889 | -7.576 | -5.164 | -5.832 | -9.823 | -0.381 | -1.924 | -0.972 | 2.427 | 3.223 | 2.512 | 0.632 |
Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | -116.64 | -1.113 | -0.028 | -0.113 | -0.049 | 0.138 | 0.215 | 0.238 | 0.094 |
Total Other Income Expenses Net
| -0.571 | -0.757 | -0.719 | -0.075 | -0.089 | -0.157 | -0.064 | -0.141 | -0.215 | 0 | 0.297 | -0.003 | 0 | 0.016 |
Income Before Tax
| -20.734 | -15.878 | -12.608 | -7.651 | -5.253 | -5.989 | -9.886 | -0.522 | -2.139 | -0.972 | 2.724 | 3.22 | 2.512 | 0.648 |
Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | -119.78 | -1.12 | -0.038 | -0.126 | -0.049 | 0.155 | 0.214 | 0.238 | 0.097 |
Income Tax Expense
| -2.094 | 0.757 | 0.599 | 0.079 | -0.2 | 0.157 | 0.48 | -0.048 | -0.783 | -0.005 | 0.766 | 0.996 | 0.843 | 0.21 |
Net Income
| -18.64 | -16.635 | -13.207 | -7.73 | -5.053 | -5.989 | -10.366 | -0.473 | -1.356 | -0.967 | 1.958 | 2.224 | 1.669 | 0.438 |
Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | -119.78 | -1.174 | -0.034 | -0.08 | -0.049 | 0.112 | 0.148 | 0.158 | 0.065 |
EPS
| -1.54 | -1.58 | -1.7 | -1.22 | -0.96 | -1.95 | -3.13 | -0.14 | -0.41 | -0.29 | 0.59 | 0.68 | 0.51 | 0.088 |
EPS Diluted
| -1.54 | -1.58 | -1.7 | -1.22 | -0.96 | -1.95 | -3.13 | -0.14 | -0.41 | -0.29 | 0.59 | 0.67 | 0.49 | 0.074 |
EBITDA
| -19.435 | -15.026 | -11.913 | -7.432 | -4.663 | -5.674 | -3.028 | 0.13 | -1.411 | 2.157 | 3.034 | 3.68 | 2.81 | 0.8 |
EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | -113.48 | -0.343 | 0.009 | -0.083 | 0.109 | 0.173 | 0.245 | 0.266 | 0.119 |